13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE 13D/A Filed 2026-06-15 Event 2026-06-11 SEC 0000947871-26-000624 →

ORBIMED ADVISORS LLC → Shattuck Labs, Inc. STTK

Stake: — Shares: 9,021,127 Class: Common Stock, par value $0.0001 per share
Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 29/100 · Filer 90d Win Rate: 25% · Hist. 90d Edge: -5.4%
  • Filer track record (12 filings): 25% 90d win rate, +0.0% 90d edge
  • Held by 1 tracked 13F institutional manager
  • Elevated short days-to-cover (7.2 DTC)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)
3 transactions
2 buys · 0 sales · 1 awards/exercises
Issuer Cluster
4 13D/G filings on this issuer
3 other filings besides this one
Filer Track Record
145 filings by this filer
144 other filings in the data moat
Short Interest · settle 2026-10-15
DTC 7.24
10,440,338 shares short · -4.6% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers
1 holder · $3.90M
Point72 Asset Mgmt

Post-Filing Returns · since 2026-06-11 on STTK

+1 day
0.0%
+5 days
0.0%
+30 days
-11.4%
+60 days
—
+90 days
—
+180 days
—

Anchor price 7.26 on closest trading day on/after 2026-06-11. Source: Yahoo Finance daily adj_close (split + dividend adjusted).

Form 4 Insider Transactions · last 365d

DateInsiderRoleTypeSharesPriceValue
2026-05-29 Boudreau Helen M director Award 81,000 $5.95 $482K
2026-05-15 Stout Stephen officer Award 12,805 $1.08 $14K
2026-05-15 Stout Stephen officer Option exercise 12,805 $1.08 $14K

Other 13D/G Filings on Shattuck Labs, Inc.

FiledFormFilerStakeShares
2026-07-17 SCHEDULE 13D/A Redmile Group, LLC 9.90% 10,019,421 view →
2026-06-17 SCHEDULE 13G Deep Track Capital, LP — — view →
2026-06-11 SCHEDULE 13D/A Redmile Group, LLC 9.90% 9,819,084 view →

Other Filings by ORBIMED ADVISORS LLC

FiledFormIssuerStakeShares
2026-10-08 SCHEDULE 13D/A ArriVent BioPharma, Inc. 5.80% 2,875,962 view →
2026-10-02 SCHEDULE 13D ADARx Pharmaceuticals, Inc. 14.00% 14,913,764 view →
2026-09-25 SCHEDULE 13D Electra Therapeutics, Inc. 11.00% 6,885,170 view →
2026-09-10 SCHEDULE 13D/A Braveheart Bio, Inc. 13.50% 12,175,159 view →
2026-08-18 SCHEDULE 13D BlossomHill Therapeutics, Inc. 8.90% 2,714,279 view →
2026-08-18 SCHEDULE 13D Braveheart Bio, Inc. 17.20% 12,175,159 view →
2026-08-10 SCHEDULE 13D/A MBX Biosciences, Inc. — 3,074,853 view →
2026-08-05 SCHEDULE 13D Yarrow Bioscience, Inc. 9.97% 266,306 view →
2026-07-29 SCHEDULE 13D Scribe Therapeutics, Inc. 7.20% 1,348,825 view →
2026-07-20 SCHEDULE 13D/A Q32 Bio Inc. — 4,127,987 view →
2026-06-24 SCHEDULE 13D/A Enliven Therapeutics, Inc. ELVN — 6,774,507 view →
2026-06-17 SCHEDULE 13D/A Enliven Therapeutics, Inc. ELVN 10.93% 7,634,630 view →
2026-06-01 SCHEDULE 13D/A Q32 Bio Inc. QTTB — 4,127,987 view →
2026-04-10 SCHEDULE 13D/A Adicet Bio, Inc. ACET 8.80% 844,787 view →
2026-01-27 SCHEDULE Corvus Pharmaceuticals, Inc. CRVS 10.30% 8,609,091 view →
2025-10-10 SCHEDULE Adicet Bio, Inc. ACET 9.60% 14,772,598 view →
2025-09-30 SCHEDULE MBX Biosciences, Inc. MBX 9.00% 4,002,887 view →
2025-07-21 SCHEDULE Passage BIO, Inc. PASG 7.82% 243,878 view →
2025-05-14 SCHEDULE Corvus Pharmaceuticals, Inc. CRVS 12.20% 9,785,423 view →
2025-04-11 SCHEDULE Compass Therapeutics, Inc. CMPX 11.00% 15,219,994 view →
Showing 20 of 144

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →